DeepMed Research

Tianjin Hemay Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Hemay022+AI
Drug: Lapatinib+Capecitabine

First Posted Date: 2024-03-15

Last Posted Date: 2025-04-22

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 339

Registration Number: NCT06313983

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis

Phase 2

Completed

Conditions: Active Ankylosing Spondylitis

Interventions: Drug: Hemay005

First Posted Date: 2022-06-07

Last Posted Date: 2024-01-11

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 90

Registration Number: NCT05407246

Locations: 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, Hubei, China
🇨🇳
Chenzhou first people's Hospital, Chenzhou, Hunan, China
🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Hefei, Anhui, China

and more 8 locations

A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Hemay007 800 mg QD group
Drug: Hemay007 1200 mg QD group
Drug: Hemay007 600 mg QD group
Drug: Hemay007 placebo group

First Posted Date: 2022-02-18

Last Posted Date: 2024-03-01

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 140

Registration Number: NCT05247216

Locations: 🇨🇳
Ningxia Hui Autonomous Region People's Hospital, Yinchuan, Ningxia, China
🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China

and more 38 locations

A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Placebo
Drug: 60mg Hemay005

First Posted Date: 2021-04-09

Last Posted Date: 2024-01-16

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 306

Registration Number: NCT04839328

Locations: 🇨🇳
Peking University People's Hospital, Peking, Beijing, China

Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Hemay005

First Posted Date: 2021-04-08

Last Posted Date: 2024-03-06

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 12

Registration Number: NCT04837235

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China

A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease

Phase 2

Terminated

Conditions: Behçet Disease

Interventions: Drug: Hemay005
Other: Placebo

First Posted Date: 2020-10-30

Last Posted Date: 2022-06-21

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 89

Registration Number: NCT04609397

Locations: 🇨🇳
Peking University Shougang Hospital, Beijing, Beijing, China
🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳
Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University, Guangzhou, Guangdong, China

and more 28 locations

A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Hemay808

First Posted Date: 2020-04-20

Last Posted Date: 2024-03-01

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 148

Registration Number: NCT04352595

Locations: 🇨🇳
Dermotology hospital, Chinese academy of medical science, Nanjing, Jiangsu, China
🇨🇳
Ningbo second hospital, Ningbo, Zhejiang, China

Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Placebos
Drug: 15mg Hemay005

First Posted Date: 2019-09-25

Last Posted Date: 2021-10-13

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 216

Registration Number: NCT04102241

Locations: 🇨🇳
Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

A Phase I Clinical Study of Hemay808

Phase 1

Completed

Conditions: Safety Issues

Interventions: Drug: Placebo
Drug: Hemay808

First Posted Date: 2019-09-24

Last Posted Date: 2020-04-27

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 42

Registration Number: NCT04100642

Locations: 🇨🇳
Dermotology hospital, Chinese academy of medical science, Nanjing, Jiangsu, China

Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Hemay007

First Posted Date: 2019-06-06

Last Posted Date: 2024-03-01

Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Target Recruit Count: 70

Registration Number: NCT03977480

Locations: 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳
Zhengzhou People's Hospital, Zhengzhou, Henan, China

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy